Journal Article

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

Lafferty, Tara K., Chen, Yijun, Zetterberg, Henrik, Lee, Jihui, Berman, Sarah B., Snitz, Beth E., Kamboh, M. llyas, Zeng, Xuemei, Klunk, William E., Lopez, Oscar I., Pfister, Anna, Kofler, Julia, Pascoal, Tharick A., Cohen, Anne D., Sehrawat, Anuradha, Tudorascu, Dana L., Blennow, Kaj, Karikari, Thomas K., Sweet, Robert A., Ikonomovic, Milos D., Villemagne, Victor L.

2024

Overview

Alzheimer’s disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD therapeutic trials and monitor treatment effects. However, the lack of standardization of how blood samples and collected, processed, stored analyzed and reported can affect the reproducibility of these biomarker measurements, potentially hindering progress toward their widespread use in clinical and research settings. To help address these issues, we provide fundamental guidelines developed according to recent research findings on the impact of sample handling on blood biomarker measurements. These guidelines cover important considerations including study design, blood collection, blood processing, biobanking, biomarker measurement, and result reporting. Furthermore, the proposed guidelines include best practices for appropriate blood handling procedures for genetic and ribonucleic acid analyses. While we focus on the key blood-based AD biomarkers for the AT(N) criteria (e.g., amyloid-beta [Aβ]40, Aβ42, Aβ42/40 ratio, total-tau, phosphorylated-tau, neurofilament light chain, brain-derived tau and glial fibrillary acidic protein), we anticipate that these guidelines will generally be applicable to other types of blood biomarkers. We also anticipate that these guidelines will assist investigators in planning and executing biomarker research, enabling harmonization of sample handling to improve comparability across studies.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Advertising executives / Alzheimer Disease - blood / Alzheimer Disease - diagnosis / Alzheimer's disease / Amyloid beta-Peptides - blood / Biobanking / Biological markers / Biological Specimen Banks - standards / Biomarkers - blood / Biomedical and Life Sciences / Biomedicine / Blood banks / Blood biomarker / Diagnosis / Ethylenediaminetetraacetic acid / Guideline / Humans / Measurement / Molecular Medicine / Neurodegeneration / Neurology / Neurosciences / Neurovetenskaper / Preanalytical factors / Research Design - standards / Specimen Handling - methods / Specimen Handling - standards / Standardization / tau Proteins - blood